Nautilus Biotechnology Overview
Latest P/E ratio for Nautilus Biotechnology: -2.15 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-2.15
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Nautilus Biotechnology posts a P/E ratio of -2.15. That is below the Healthcare sector average of 25.3. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Healthcare stocks, a P/E ratio near 25.3 is typical. Nautilus Biotechnology's -2.15 is lower that level. That is roughly 108.5% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Nautilus Biotechnology's P/E ratio of -2.15 comes from dividing a price-based measure by a related financial statistic. Changes can come from the stock price moving, the underlying fundamental shifting, or both. Track both the level and the trend — a rising multiple on falling fundamentals is a different story than a rising multiple on rising earnings.
Context for NAUT's P/E ratio usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 25.3), and (3) consistency with growth and profitability. This page covers the first two; Nautilus Biotechnology's other metric pages and overview cover the third.
Judging Nautilus Biotechnology against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in P/E ratio easier to interpret. Start with -2.15 here, then scan peer and history charts to see if the gap is persistent.
